Literature DB >> 10649571

Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1.

X Lin1, B Antalffy, D Kang, H T Orr, H Y Zoghbi.   

Abstract

The expansion of an unstable CAG repeat causes spinocerebellar ataxia type 1 (SCA1) and several other neurodegenerative diseases. How polyglutamine expansions render the resulting proteins toxic to neurons, however, remains elusive. Hypothesizing that long polyglutamine tracts alter gene expression, we found certain neuronal genes involved in signal transduction and calcium homeostasis sequentially downregulated in SCA1 mice. These genes were abundant in Purkinje cells, the primary site of SCA1 pathogenesis; moreover, their downregulation was mediated by expanded ataxin-1 and occurred before detectable pathology. Similar downregulation occurred in SCA1 human tissues. Altered gene expression may be the earliest mediator of polyglutamine toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649571     DOI: 10.1038/72101

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  120 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

3.  Suppression of calbindin-D28k expression exacerbates SCA1 phenotype in a disease mouse model.

Authors:  Parminder J S Vig; Jinrong Wei; Qingmei Shao; Maripar E Lopez; Rebecca Halperin; Jill Gerber
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

Review 4.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

5.  RORalpha coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways.

Authors:  David A Gold; Sung Hee Baek; Nicholas J Schork; David W Rose; DeLaine D Larsen; Benjamin D Sachs; Michael G Rosenfeld; Bruce A Hamilton
Journal:  Neuron       Date:  2003-12-18       Impact factor: 17.173

Review 6.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

7.  Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.

Authors:  Emma M Perkins; Yvonne L Clarkson; Nancy Sabatier; David M Longhurst; Christopher P Millward; Jennifer Jack; Junko Toraiwa; Mitsunori Watanabe; Jeffrey D Rothstein; Alastair R Lyndon; David J A Wyllie; Mayank B Dutia; Mandy Jackson
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

8.  Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23.

Authors:  Georgy Bakalkin; Hiroyuki Watanabe; Justyna Jezierska; Cloë Depoorter; Corien Verschuuren-Bemelmans; Igor Bazov; Konstantin A Artemenko; Tatjana Yakovleva; Dennis Dooijes; Bart P C Van de Warrenburg; Roman A Zubarev; Berry Kremer; Pamela E Knapp; Kurt F Hauser; Cisca Wijmenga; Fred Nyberg; Richard J Sinke; Dineke S Verbeek
Journal:  Am J Hum Genet       Date:  2010-10-28       Impact factor: 11.025

9.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

Review 10.  Neurological and Motor Disorders: Neuronal Store-Operated Ca2+ Signaling: An Overview and Its Function.

Authors:  Sunitha Bollimuntha; Biswaranjan Pani; Brij B Singh
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.